Ray of hope for people with severe skin condition

9 September 2020
2020_biomarker_biotech_test_big

Shares in London-based Amryt Pharma (AIM: AMYT) were up around 50% in morning trading on Tuesday, following positive top-line results from a Phase III study of Filsuvez (oleogel-S10), a topical therapeutic gel.

The firm, which is focused on serious and life-threatening diseases, said the EASE trial met its primary endpoint in the treatment of a rare skin condition.

Amryt has been trialing the therapy as an option for dystrophic and junctional Epidermolysis bullosa (EB), a serious, chronic and rare condition for which there are no approved treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology